HCPLive Network

Fostamatinib Is Safe but Ineffective in Treating in Rheumatoid Arthritis

An oral spleen tyrosine kinase inhibitor known as Fostamatinib disodium has been discovered to be a safe but ineffective treatment of patients suffering from rheumatoid arthritis (RA) who failed biologic therapies.
 
According to a study published in the February issue of Arthritis & Rheumatism, Mark C. Genovese, M.D., of Stanford University in Palo Alto, Calif., and his colleagues created a double-blind, placebo controlled study with the intention of analyzing the effectiveness and safety of fostamatinib disodium (R788).
 
“Safety results appeared to suggest that 100 mg twice a day of R788 was a tolerable dose for chronic administration in RA,” said researchers of the study done, who said that while the dosage is not dangerous for patients, their research proves it to not be as effective as they had hoped.

The study consisted of 229 patients, all living with active RA, who had no response to biologic therapies. The participants of the study were randomly selected to be given 100 milligrams of fostamatinib or a placebo.

The chief goal and what was considered to be the finish line for these patients was the American College of Rheumatology 20 percent improvement (ACR20) response following three months of the treatment.

Secondary aims consisted of changes in inflammation and damage to the joints, which was evaluated by magnetic resonance imaging (MRI) and changes in the disease activity score.

As far as the primary goals were considered, the researchers of the study discovered that the ACR20 responses did not vary drastically between the group selected to receive fostamatinib and the group receiving the placebo.  There was, however, a significant variation in the ACR20 among participants who entered the study with elevated C-reactive protein.

Secondary outcomes, on the other hand, proved to show distinction between the two groups: The group receiving fostamatinib showed improved synovitis scores on MRI and in C-reactive protein. The results may have been affected by “baseline differences in steroid use, prior biologic use, and MRI synovitis scores”, according to DoctorsLounge.

The researchers are not through with the treatment for RA patients just yet, however. “There appears to be sufficient grounds to study R788 in this refractory population again, with some important lessons learned from this phase II study,” the researchers of the study wrote.
 

Further Reading
Results from a 12-week study show that treatment with once-daily, single-entity hydrocodone formulated with abuse-deterrent properties is safe and effective compared with placebo.
Although methadone accounts for only 2 percent of opioid prescriptions, it caused nearly one in three prescription opioid overdose deaths in 2012, a six-fold increase from 2009, according to the CDC.
Because there is no objective test for pain, and because each patient’s experience of his or her painful condition is subjective and unique, physicians who treat these patients must process a variety of symptoms, signs, and cues to determine whether they can trust their patient’s narrative.
Systemwide changes are necessary to prevent excessive healthcare spending, and so are tools to help consumers make better, more informed medical choices, according to a white paper published in June by Vitals.
Study results show that patients diagnosed with fibromyalgia often discontinue treatment. Those that do not frequently augment their initial treatment regimen with one or more additional medications, including some that are not recommended by current guidelines.
The patient-reported painDETECT questionnaire has been shown to accurately and reliably identify neuropathic pain across a range of conditions.
Knowledge of dietary supplement properties, uses, and contraindications is highly relevant to any health care practitioner that treats patients with chronic pain. Data shows that the top four reasons for supplement use are back pain, neck pain, joint pain, and arthritis.
More Reading